Write a comment
Norbrook has announces a CEO succession plan to build on the business transformation that has taken place in recent years, with current CEO Liam Nagle who has been with the company 8 years being replaced by Italian born Andrea Iucci later this year.
The Newry based company has a clear strategic plan and multi-year capital investment programme in place that aims to position the company strongly for the future.
With this solid foundation in place, Liam Nagle, Chairman & CEO, with the Board, decided to consider CEO succession planning to support the company as it moves to the next phase. Given the strength of the business operationally, it was agreed that a leader with a strong commercial background was critical to lead Norbrook in the future.
The CEO appointment was the conclusion of an extensive global search process led by a subset of the Board and supported by an executive search firm. Following this, Norbrook is delighted to appoint Andrea Iucci, formerly Senior Vice President and Corporate Office, EMEA in IDEXX, as CEO, who will take over from Liam later this year. Liam will continue his role as Chairman of the Board.
Since he joined Norbrook Laboratories in 2015, Liam Nagle’s strategic vision, operational focus, drive, and energy, have enabled Norbrook to deliver improvements in all areas of the business. In that time, the company has strengthened its talent pool, enhanced its manufacturing capability, achieved higher quality standards, and created a culture based on core values. With the strategic plan and multi-year investment programme delivered, the company is well-positioned for future growth.
Liam Nagle, CEO & Chairman Board of Directors at Norbrook, said: “I would like to thank the Board of Directors, Shareholders, Norbrook employees, and our loyal Customers, for their support in my time as CEO. I truly believe we have a great business, in a great sector, and I look forward to Andrea leading the business through its next phase. I am honoured to continue my involvement in Norbrook as Chairman of the Board, and will work closely with Andrea to ensure a smooth transition.”
Andrea Iucci commented: “I am excited by the opportunity to join Norbrook Laboratories and continue the great work done by the team. I look forward to leveraging my commercial background and years of experience to build on Norbrook’s strong foundation and drive significant growth globally”.
Lady Ballyedmond, Vice-Chair Board of Directors of Norbrook said: “On behalf of the Board, I would like to thank Liam for his leadership, vision, and commitment over the past nine years. As CEO, and latterly Chairman and CEO, he has led the transformation of Norbrook, leaving the Company well-equipped to compete in the years ahead. I am delighted to welcome Andrea as our new CEO. Together with the rest of the Board, I am confident that Andrea’s skills and experience will help us to create a good future for Norbrook, building on the strong foundations already in place.”
About Andrea Iucci
Andrea Iucci was born and raised in Rome and joined IDEXX in 2017 where he was Vice President for Companion Animal Central and Eastern Europe, following a distinguished career of over two decades in the commercial pharmaceutical sector. During this time, he focused on expanding markets in Europe, the Middle East, Africa, China, Brazil, and Italy. Under Andrea's leadership, the IDEXX EMEA region almost doubled its revenues in the last five years.
In recognition of his valuable contributions, he was promoted to the position of Senior Vice President and Corporate Office, EMEA in 2020. In this role, Andrea played a pivotal part in implementing the Operational and Commercial Ecosystem in multiple countries, leading to successful business expansion in key European markets. Throughout these strategic endeavours, he prioritised customers, regularly visiting practices to better understand their needs and cultivate partnerships to help grow their practices. His commitment to strategic thinking to develop people and businesses is present in his daily work.
Before joining IDEXX, Andrea worked at Abbott, where he held various positions, starting in 2012. He initially served as the General Manager for the Czech Republic and Slovakia in the EPD division. Later, he assumed the role of Regional Director for Abbott Pharmaceutical Division in Central Europe, followed by Director of the DVP, Great China Pediatric, Abbott Nutrition International in Shanghai, China, in March 2016. Prior to his tenure at Abbott, Andrea gained valuable experience in Marketing, Sales, and Regional Management roles with renowned companies like Pfizer, J&J, Zambon, and company management at Sigma Tau Group – Avantgarde.
From 2008 to 2012, during his tenure at the family-owned Sigma Tau Group - Avantgarde, Andrea successfully led the company with a diverse portfolio of around 150M Euro. This portfolio included prescribed products, branded generics, OTC medications, oral care, and food supplements. Under his guidance, the company experienced significant growth, owing to well-executed commercial and innovation strategies, disciplined investment decisions, and a strong focus on talent developments.
